The above results indicate that MA alleviates the resistance of lung cancer cells to osimertinib, mainly by inhibiting the KRAS-ERK pathway, as well as the KRAS-NRF2-SLC7A11 and FTH1 ferroptosis axis. The gene discussed is KRAS; the disease is lung carcinoma.